Introduction
============

Formation of biofilms represents an important virulence factor of the Gram-positive opportunist *Staphylococcus aureus* ([@B50]; [@B54]), one of the most common causatives of a variety of biofilm-associated diseases such as osteomyelitis, endocarditis, skin and skin structure infection (SSSI) as well as foreign body associated infections, commonly leading to the development of sepsis ([@B9]). Therefore, infections caused by *S. aureus* are associated with increased morbidity and mortality ([@B4]).

Biofilms are complex three-dimensional microbial communities attached to a multitude of surfaces representing the preferred life-style of the bacteria in natural and artificial habitats ([@B17]; [@B8]). In biofilms, bacterial cells are embedded in an extracellular matrix of organic polymers such as polysaccharides, peptides, and extracellular DNA that are synthesized and released by the microbes themselves ([@B45]; [@B2]; [@B20]). The matrix drastically reduces the susceptibility to different outer stress factors ([@B16]) indicated by up to 1000-fold higher tolerance to antimicrobials of the biofilm-embedded cells compared to their planktonic counterparts ([@B11]; [@B65]). Treatment of chronic infections is often complicated due to the presence of bacterial biofilm on the surface of the wound that detain the healing process ([@B15]; [@B66]; [@B64]). In addition, biofilms demonstrate increased robustness against the host immune system leading to recurrent and/or persistent chronic infections. In addition, the genotypic resistance of bacteria can increase the overall antimicrobial resistance of the biofilm-embedded bacteria providing the so called herd-protection for the susceptible co-occupants. The conjugative acquisition of methicillin resistance is also a strong limiting factor for the antimicrobial therapy efficacy of *S. aureus* caused infections. Infections by methicillin-resistant *S. aureus* strains (MRSA) have even poorer outcomes ([@B10]) requiring alternative therapeutic options.

In general, only very few antibiotics are capable of directly attacking bacterial biofilms. For example, rifampicin in combination with other antibiotics such as β-lactam is often used against persisting staphylococcal biofilms ([@B23]), because bacteria rapidly develop rifampicin resistance under treatment. Experimental data also suggest that ribosome-active antibiotics (such as linezolid or clindamycin) might be effective against staphylococcal biofilms because of their comparable suppressive effect on the expression of various virulence factors ([@B30]). However, clinical evidence is still missing; thus, nowadays neither linezolid nor clindamycin are recommended for treatment of biofilm-associated staphylococcal infections.

Investigations on alternative treatment options against biofilm-associated infections is largely based upon the use of specialized agents (such as quaternary ammonium compounds, curcumin or chlorquinaldol) that in combinations with antibiotics provide high local drug concentrations avoiding systemic adverse effects ([@B31]; [@B60]; [@B6]). Among various compounds exhibiting antimicrobial and anti-biofilm activities, the derivates of 2(5*H*)-furanone have been intensively studied in last two decades. In the nature, furanones are known to exhibit many different functions, such as intra- and inter-species signaling and communication, attractant molecules and pheromones, antimicrobials, and anti-carcinogens ([@B22]; [@B17]; [@B8]). Several studies have reported the ability of synthetic furanones to inhibit biofilm formation of various bacteria ([@B62]; [@B27]; [@B47]; [@B21]). While many 2(5*H*)-furanone derivatives interfere with AI-II quorum-sensing systems of Gram-negative bacteria thereby blocking the biofilm growth ([@B62]), a number of furanones were shown to repress the biofilm formation by *Bacillus subtilis* and *Staphylococci* ([@B26]; [@B61]; [@B47]; [@B34]). In particular, [@B47] reported that (*Z*)-5-(bromomethylene)furan-2(5*H*)-one completely repressed the biofilm formation by *S. epidermidis* without any irritative or genotoxic effects. In contrast, brominated furanone increased the production of the extracellular matrix by *S. aureus* ([@B73]) indicating no universality in the effects of these compounds on bacterial cells. Besides the biofilm repression effects, in several other studies furanone derivatives were reported to exhibit bactericidal activity against gram positive bacteria ([@B61]; [@B37]).

It has been previously shown that the introduction of *l*-menthol moiety into carbamate derivatives significantly increases their anti-biofilm properties toward multidrug-resistant *S. aureus* ([@B63]). Several other studies reported that sulfonyl-containing compounds efficiently repressed the growth and biofilm formation by *Staphylococci* ([@B51]; [@B39]; [@B48]). Therefore, we aimed to investigate the antimicrobial activity of a novel 2(5*H*)-furanone derivative (**F105**) possessing two pharmacophores, a sulfonyl group and an *l*-menthol moiety. We found synergy of **F105** with aminoglycosides against planktonic *S. aureus* and demonstrated their attractive activity toward the biofilm-embedded bacteria.

Materials and Methods {#s1}
=====================

Chemistry
---------

3-Chloro-5(*S*)-\[(1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyloxy\]-4-\[4-methylphenylsulfonyl\]-2(5*H*)-furanone (**F105**) was synthesized in three steps. For the detailed description of compounds preparation and characterization, we refer to the Supplementary Data, available online. The stock solutions of **F105** were prepared by diluting powders in pure DMSO (Sigma--Aldrich, Saint-Quentin Fallavier, France) at the concentration of 20 g/L. To solubilize the furanone at high concentrations in medium, pluoronic acid F-127 (Sigma--Aldrich) (10% stock solution in DMSO) was added to the final concentration of 0.1%. Working solutions were prepared in bacterial growth medium such that the final concentrations of DMSO 5% have been obtained, which was next verified to be non-toxic for the bacterial strains tested. All conventional antibiotics were purchased from Sigma.

Strains and Culture Conditions
------------------------------

A methicillin sensitive *Staphylococcus aureus* ATCC^®^29213 (MSSA) and a methicillin resistant *S. aureus* strain ATCC^®^43300 (MRSA) (both laboratory strains) as well as 10 clinical MRSA isolates provided by the Republican Clinical Hospital, Laboratory of Clinical Bacteriology in Kazan were used in this study (see **Table [1](#T1){ref-type="table"}**). The bacterial strains were stored in 10% (V/V) glycerol stocks at -80°C and freshly streaked on blood agar plates (BD Diagnostics) following by their overnight growth at 35°C before use. Fresh colony material was used to adjust an optical density to 0.5 McFarland (equivalent to 10^8^ cells/mL) in 0.9% NaCl solution that was used as a working suspension.

###### 

The antimicrobial effects of **F105** expressed as MIC, MBC, BPC and MBEC against *S. aureus* isolates in mg/L.

  *S. aureus* strain   MIC   MBC   BPC          MBEC
  -------------------- ----- ----- ------------ -------------
  ATCC 29213 (MSSA)    10    40    40 (40^∗^)   80 (160^∗^)
  ATCC 43300 (MRSA)    20    80    80 (40^∗^)   80^∗^
  *S. aureus* 1053     10    20    20           n.d.^∗∗^
  *S. aureus* 1130     10    40    20           n.d.
  *S. aureus* 1131     10    20    20           n.d.
  *S. aureus* 1134     10    20    20           n.d.
  *S. aureus* 1145     10    40    20           n.d.
  *S. aureus* 1163     10    40    40           n.d.
  *S. aureus* 1167     10    20    20           n.d.
  *S. aureus* 1168     10    20    20           n.d.
  *S. aureus* 1173     10    40    20           n.d.
  *S. aureus* 2020     10    40    20           n.d.
                                                

MIC and MBC were assessed by the micro dilution method, BPC and MBEC by the drop plate method or by CLSM

∗

.

∗

The values in parentheses represent the concentration at which biofilm formation was visibly inhibited in CLSM-analysis.

∗∗

n.d., not determined.

Determination of the Minimal Inhibitory (MIC) and the Minimal Bactericidal Concentrations (MBC) of F105
-------------------------------------------------------------------------------------------------------

The MIC of furanone **F105** was determined by the broth microdilution method in 96-well microtiter plates (Eppendorf) according to the EUCAST rules for antimicrobial susceptibility testing ([@B44]) with minor modifications to account for the decreased solubility of the compound. Briefly, the 10^8^ cells/mL bacterial suspension was subsequently diluted 1:300 with Mueller-Hinton broth (MH) (Carl Roth GmbH, Germany), cation-adjusted with 20 mg/L Ca^2+^ and 10 mg/L Mg^2+^ and supplemented with various concentrations of **F105** in microwell plates to obtain a 3 × 10^5^ cells/mL suspension. To solubilize the furanone at high concentrations in medium, pluoronic acid F-127 (Sigma--Aldrich) (10% stock solution in DMSO) was added to the final concentration of 0.1%. The final concentration of DMSO was adjusted to 5% in all bacterial cultures. The concentrations of **F105** ranged from 1.25 to 160 mg/L. Besides the usual double dilutions, additional concentrations were included in between. The cultures were incubated at 35°C for 24 h. The MIC was determined as the lowest concentration of furanone for which no visible bacterial growth could be observed after 24 h of incubation.

To determine the MBC, the CFU/mL were further evaluated in culture liquid from wells without visible growth. The **F105** concentration reducing the number of viable cells by at least three orders of magnitude was considered as MBC according to the recommendation of the [@B19].

Synergy Testing by Checkerboard Assay
-------------------------------------

The checkerboard assay was performed similarly to the MIC testing in 96-well microtiter plates (Eppendorf). Each plate contained serial dilutions of **F105** in 0.1% pluoronic acid F-127 and different antibiotics in a checkerboard fashion as described previously ([@B18]). Briefly, the final concentrations of both compounds ranged from 1/16× to 4× MIC for **F105** and from 1/256× to 4× MIC for the antibiotics. In total, 11 dilution steps of antibiotics and 7 dilution steps of **F105** were analyzed. The microwell plates were incubated at 35°C for 24 h. Each test was performed in triplicate and included a growth control with neither antibiotic nor **F105** addition. The fractional inhibitory concentration index (FICI) for each double combination was calculated as
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The FICIs were counted from the concentrations in the first non-turbid well found in each row and column along the turbidity/non-turbidity interface and the lowest FICI value was used to characterize the synergy. For the FICI interpretation we refer to [@B14] and [@B56]: FICI \< 0.5 corresponds to synergy, 0.5 \< FICI \< 4 corresponds to either additive effects or indifference, while FICI \> 4 corresponds to antagonism.

Analysis of the Biofilm Prevention Concentration (BPC) of F105
--------------------------------------------------------------

To determine the BPC of **F105**, two methods have been applied, including the modified crystal-violet staining ([@B52]) and the drop plate approach ([@B29]). Briefly, the bacterial culture was adjusted to 5 × 10^5^ cells/mL in the MH broth and seeded into 24-well polystyrene culture plates (Eppendorf). **F105** was added in serial dilutions to the final concentrations between 1.25 and 160 mg/L following by the cells growth under static conditions for 24 h at 35°C. For the crystal violet staining, the liquid culture was removed after 24 h of incubation and the plates were washed twice with PBS (pH 7.4) and dried. Then 1 ml of the 0.5% crystal violet solution (Sigma) in 96% ethanol was added per well, followed by 20 min incubation. Next the crystal violet solution was removed and the plate was washed 3 times with PBS. After 30 min air drying, 1 ml of 96% ethanol was added to resolubilize the bound crystal violet, and the absorbance was measured at 570 nm with the microplate reader Infinite 200 Pro (Tecan). Cell-free wells incubated with pure medium subjected to all staining manipulations were used as control.

Alternatively, the viability of cells was evaluated by the drop plate approach with minor modifications ([@B29]). Serial 10-fold dilutions from each well were prepared and 5 ml of suspension was dropped onto LB agar plates in five repeats. CFU/mL were counted and averaged from those drops containing 5--30 colonies. To evaluate the viability of biofilm-embedded cells, wells were washed several times with phosphate-buffered saline (PBS) to remove both non-adherent and detached cells. The washed biofilms were suspended in PBS by scratching the well bottoms with following treatment in a sonicator bath for 2 min at 20 kHz to favor the disintegration of bacterial clumps, and viable cells were counted by the drop plate method as described above.

### Time-Kill Assay

Time-kill curves were obtained by growing MSSA in MH medium in the presence of **F105** at concentrations of 0.5× MBC, 1× MBC, and 2× MBC. The starting bacterial suspension was adjusted to the 5 × 10^7^ cells/mL concentration. Cells were then cultivated in 6-well microtiter plates without shaking at 35°C for 12 h and samples were taken every 4 h, serially diluted 1:10 and plated onto agar plates. The CFU/mL was counted after incubation at 35°C for at least 16 h.

### Determination of Anti-biofilm Activity of F105 by CLSM

To additionally compare the BPC of MSSA and MRSA standard strains by a microscopic method, the biofilms were grown in the presence of **F105** as descried above. To determine the minimal biofilm eradicating concentration (MBEC), the biofilms were grown without **F105** under static conditions for 24 h at 35°C. Subsequently, the supernatants were carefully removed and the biofilms were treated with 500 μL of **F105** solutions with various concentrations between 5 and 160 mg/L serially diluted in MH broth, and cultivation was continued for 24 h at 35°C. The effect of ampicillin, gentamicin, and benzalkonium chloride on the biofilm-embedded cells was analyzed similarly.

For both BPC and MBEC determination, the liquid cultures were carefully removed and the biofilms were washed once with 300 μl of 0.9% NaCl solution. The biofilms were stained using LIVE/DEAD BacLight Bacterial Viability Kit for microscopy (Life Technologies GmbH) according to manufacturer's protocol. Stained biofilms were analyzed under vital conditions using an inverted confocal laser scanning microscope (CLSM) Carl Zeiss LSM 780 (Carl Zeiss AG) at green (522 nm) and red (635 nm) filters, respectively, using laser excitation at 490 nm as described previously ([@B38]; [@B3]). An area of approximately 100 μm (X) × 100 μm (Y) was screened in 1 μm Z-intervals (Z-stack). The biofilm microscopy data were processed using ZEN 9.0 software (Carl Zeiss AG).

The BPC was considered as the furanone concentration at which the complete absence of the biofilm assessed with crystal violet staining was observed ([@B59]). **F105** concentrations reducing the viable cells by at least 3 orders of magnitude in the biofilm matrix were considered as MBEC.

Determination of F105 Cytotoxicity
----------------------------------

Cytotoxicity of **F105** was determined using the CellTiter 96^®^ Aqueous Non-Radioactive Cell Proliferation Assay (Promega) using MCF-7 cells. The cells were cultured in DMEM -- Dulbecco's Modified Eagle's Medium (Sigma--Aldrich) supplemented with 10% FBS, 2 mM [L]{.smallcaps}-glutamine, 100 mg/L penicillin and 100 mg/L streptomycin. Cells were seeded in 96-well plates with the density of 3000 cells per well and left overnight to allow for the attachment. Cells were next cultured at 37°C and 5% CO~2~ in the presence of **F105** at various concentrations from 1.25 to 160 mg/L. After 24 h of cultivation the cells were subjected to MTS-assay based on the cellular reduction of MTS (3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2*H*-tetrazolium) by the mitochondrial dehydroxygenase using phenazinemethosulfate (PMS) as the electron coupling reagent. The MTS tetrazolium compound was bioreduced by viable cells into a colored formazan product, which was measured on Tecan Infinite 200Pro at 550 nm. The concentration required to inhibit cellular dehydrogenase activity by 50% (CC~50~ value) was calculated as recommended by the manufacturer.

The mutagenicity of **F105** was evaluated in the Ames test with *Salmonella typhimurium* TA98, TA100 and TA102 strains as described in [@B49]. The tested compound was considered to be mutagenic if the number of revertant colonies in the experiment was more than two times higher than that in the negative control (DMSO) and increased at higher **F105** concentrations ([@B57]).

Data Analysis
-------------

All experiments were performed in biological triplicates with three repeats in each run. The data were analyzed and graphically visualized using GraphPad Prism version 6.00 for Windows (GraphPad Software, United States, [www.graphpad.com](http://www.graphpad.com)). In each experiment, comparison against negative control has been performed using the non-parametric Kruskal--Wallis one-way analysis of variance test. Significant differences against respective controls were considered at *p* \< 0.05 and are specified in the corresponding figure captions. Additionally, statistical significance of time-kill curves and dose-response curves have been assessed by linear regression analysis applied in log scales where appropriate. For the regression analysis data, shown confidence intervals also correspond to *p* \< 0.05.

Results
=======

Synthesis of Furanone F105
--------------------------

The 2(5*H*)-furanone derivative **F105** **(4)** was synthesized in three steps from commercially available mucochloric acid **1** (see **Figure [1](#F1){ref-type="fig"}**). In the first stage, a mixture of diastereomers **2a** + **2b** was obtained in the reaction of mucochloric acid **1** with *l*-menthol in the presence of catalytic amounts of concentrated sulfuric acid as described previously ([@B22]). The pure stereoisomer **2a** with *S*-configuration of the carbon atom C^5^ of the γ-lactone ring was isolated in 52% yield after two recrystallizations from hexane (**Figure [1](#F1){ref-type="fig"}**).

![Synthesis of 2(5*H*)-furanone derivative **F105**.](fmicb-08-02246-g001){#F1}

Next a thiolation reaction of the isolated stereoisomer **2a** under basic catalysis was carried out. It is well-known that in the presence of triethylamine reactions of 5-alkoxy-2(5*H*)-furanones with thiols proceed with the regioselective substitution of the chlorine atom in the fourth position of the lactone ring ([@B41]; [@B43]). The reaction was performed in diethyl ether at room temperature with the equimolar ratio of furanone **2a**, *p*-thiocresol and triethylamine resulting in the novel optically pure thioether **3** with 85% yield. Thioether **3** was further subjected to oxidation to the corresponding sulfone **4** using a recently developed selective method ([@B43]). The compound **3** was treated with 10-fold excess of 33% hydrogen peroxide in acetic acid at room temperature and the novel optically pure sulfonyl derivative of 2(5*H*)-furanone **4** (studied compound **F105**, **Figure [1](#F1){ref-type="fig"}**) was isolated in the form of colorless crystals in 70% yield. The structure of compounds **2**--**4** was characterized in detail by IR and NMR spectroscopy (Supplementary Figures [S1](#SM1){ref-type="supplementary-material"}--[S5](#SM1){ref-type="supplementary-material"}).

Antimicrobial Activity of F105 on Planktonic *S. aureus*
--------------------------------------------------------

The antimicrobial properties of **F105** were determined on both methycillin-susceptible (MSSA) and -resistant (MRSA) *S. aureus* strains ATCC29213 and ATCC43300, respectively. The minimal inhibitory concentration (MIC) of **F105** for MSSA was found to be 10 mg/L (25 μM), and 20 mg/L (50 μM) for MRSA (see **Table [1](#T1){ref-type="table"}**). The minimal bactericidal concentration (MBC) value of **F105** was found to be 40 mg/L in MSSA and 80 mg/L in MRSA. The time-kill curves revealed that all cells of MSSA exposed to **F105** at concentration of 2× MBC were killed within 8 h of treatment (**Figure [2A](#F2){ref-type="fig"}**). Alternatively, 1× MBC of **F105** led to the reduction in the number of viable cells by three orders of magnitude within 12 h. The dose-response curves (**Figure [2B](#F2){ref-type="fig"}**) confirm the concentration-dependence of **F105** effect on cells viability explicitly suggesting that **F105** exhibits biocidal activity. Interestingly, our earlier results indicate that the analogs of **F105** lacking either sulfonyl group (compound **3** on the **Figure [1](#F1){ref-type="fig"}**) or *l*-menthol moiety (**F70**, 3-chloro-5-hydroxy-4-\[(4-methylphenylsulfonyl)\]-2(5*H*)-furanone) exhibited no activity against *S. aureus* ([@B43]; [@B34]) (data not shown) suggesting the requirement of both functional groups for bactericidal activity, while in other works the presence of either sulfonyl group or *l*-menthol moiety increased antibacterial effects ([@B51]; [@B39]; [@B63]; [@B48]).

![Time-kill curves of **F105** against MSSA cells. The numbers of CFU/mL were calculated by using drop plate approach **(A)** and respective dose-response curves were plotted providing residual CFU/mL as a function of exposition time **(B)**. **F105** is presented in different concentrations: untreated cells (black); 0.5× MBC (20 mg/L, blue); 1× MBC (40 mg/L, green); 2× MBC (80 mg/L, red). Full lines denote regression lines, while dashed lines denote corresponding 95% confidence intervals.](fmicb-08-02246-g002){#F2}

We additionally assessed both MIC and MBC in 10 clinical isolates exhibiting a MRSA phenotype. Both values ranged within the MIC and MBC found in the MSSA laboratory standard strain with all MICs at 10 mg/L, and MBC at 20 mg/L (*n* = 5) or 40 mg/L (*n* = 5) (**Table [1](#T1){ref-type="table"}**).

Synergistic Effects of F105 with Other Antimicrobials on *S. aureus* Planktonic Cells
-------------------------------------------------------------------------------------

The synergism of **F105** in combination with various antibiotics on the bacterial growth was analyzed by the checkerboard assay (**Table [2](#T2){ref-type="table"}** and Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Thereby synergism of **F105** was observed when combined with aminoglycosides. Particularly, the FICI values for **F105** were determined to be 0.33 ± 0.04 in combination with amikacin, 0.33 ± 0.16 with gentamicin and 0.44 ± 0.17 with kanamycin. Besides aminoglycosides, strong synergy has been observed also for benzalkonium chloride with FICI of 0.29 ± 0.09. Indifferent effects, but with relatively low FICI (between 0.51 and 0.75) indicating enhancement of antimicrobial activity were observed for **F105** in combination with daptomycin, rifampicin, ciprofloxacin, tetracycline, and linezolid; whereas the only additive effects were observed for combinations of **F105** with erythromycin and vancomycin. For deeper analysis of **F105** synergy with antimicrobials, the combined MICs of the antibiotic/**F105**-mixtures were plotted (as isoboles) and the effective concentrations of **F105** (EC~50~) leading to the twofold reduction of antibiotic's MIC were calculated (**Table [2](#T2){ref-type="table"}** and Supplementary Figure [S6](#SM1){ref-type="supplementary-material"}). The EC~50~ values of **F105** in combinations with amikacin, gentamycin, and kanamycin were determined to be 0.7, 0.7, and 1.3 mg/L, respectively. Only 0.5 mg/L of **F105** was required to reduce the MIC of benzalkonium chloride twofold. For other studied antibiotics EC~50~ values of **F105** were in the range of 4.3 and 9.5 mg/L.

###### 

MIC and ECOFF values of various antibiotics against MSSA, FICI values of those antibiotics combined with **F105** and EC~50~ of **F105** reducing twice the MIC of the appropriate antibiotic.

                          MIC^a^   ECOFF^a^   FICI~min~        EC~50~^a^
  ----------------------- -------- ---------- ---------------- -----------
  Benzalkonium chloride   1.00     ND         0.29 ± 0.09^b^   0.5
  Amikacin                1.00     8.00       0.33 ± 0.04      0.7
  Gentamicin              1.00     2.00       0.33 ± 0.16      0.7
  Kanamycin               2.00     8.00       0.44 ± 0.17      1.3
  Tetracycline            0.50     1.00       0.65 ± 0.10      4.3
  Erythromycin            1.00     1.00       0.79 ± 0.19      4.9
  Ciprofloxacin           0.50     1.00       0.68 ± 0.27      5.3
  Ampicillin              0.25     ND         0.78 ± 0.23      7.1
  Rifampicin              0.03     0.03       0.55 ± 0.02      8.3
  Daptomycin              4.00     1.00       0.51 ± 0.01      9.5
  Linezoild               4.00     4.00       0.55 ± 0.01      7.5
  Vancomycin              2.00     2.00       0.92 ± 0.14      7.9
                                                               

a

The concentrations are given in mg/L;

b

FICI is given by the mean ± SD.

Anti-biofilm Activity of F105
-----------------------------

Since the anti-biofilm activity of furanones was reported for some compounds ([@B62]; [@B27]; [@B47]; [@B21]), the biofilm preventing concentration (BPC) of **F105** for the MSSA laboratory standard strain was assessed first by two different methods. The crystal violet staining method revealed that **F105** completely inhibited the biofilm formation of the MSSA at the concentration of 20 mg/L (**Figure [3A](#F3){ref-type="fig"}**); whereas, applying direct counting of viable cell in the biofilm the BPC was found to be 40 mg/L (**Figure [3B](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Since the amount of viable planktonic cells (swimming cells) also decreased by three orders of magnitude at 20 mg/L of **F105**, we suggested that the biofilm suppression was rather the consequence of cell growth repression. The CLSM analysis confirmed the BPC of **F105** of 40 mg/L for MSSA (**Figure [4](#F4){ref-type="fig"}**), thus we estimated that these direct methods are more adequate compared to the indirect crystal violet staining. The determined BPC of MRSA was 80 mg/L according to the CFU/ml counting and 40 mg/L according to the CLSM (**Table [1](#T1){ref-type="table"}** and **Figure [4](#F4){ref-type="fig"}**). The BPC was measured by the drop plate method in the clinical MRSA isolates resulting in 20 mg/L in nine and 40 mg/L in one isolate (**Table [1](#T1){ref-type="table"}**).

![Effect of **F105** on the biofilm formation by MSSA. Cells were incubated for 24 h in the presence of different concentrations of **F105**, the biofilms were quantified after crystal-violet staining **(A)** and CFU counting **(B)**; thereby the crystal-violet method correlates with the biomass and CFU/mL with viable cells.](fmicb-08-02246-g003){#F3}

![The biofilm-preventing activity (BPC) of **F105** against MSSA **(upper)** and MRSA **(lower)** analyzed by CLSM. **F105** was added prior the inoculation with following cell grow for 24 h. The images show a plan view on a basal biofilm layer (indicated by X and Y axis) and a cross section thought the biofilm (Z axis). The scale bars indicate 10 μm.](fmicb-08-02246-g004){#F4}

To further analyze, whether **F105** not only inhibits the biofilm formation but also exhibits activity against already established biofilms, 24 h-old *S. aureus* biofilms of the MSSA and MRSA laboratory standard strains were treated with different concentrations of **F105**. The CLSM analysis of the MBEC indicated that the treatment with **F105** did not lead to any visibly remarkable decrease of the biofilm thickness (**Figure [5](#F5){ref-type="fig"}**), while the ratio of dead/viable cell increased significantly in the concentration dependent manner. Biofilm-embedded cells of MRSA were nearly completely killed at 80 mg/L of **F105**, whereas MSSA cells were killed at 160 mg/L. However, the CFU/mL of the planktonic cells and the adherent cells of MSSA biofilm cultures revealed a reduction in the number of viable cells by three orders of magnitude at 80 mg/L of **F105** for both attached and detached cells (**Figure [6](#F6){ref-type="fig"}**) indicating that CLSM results vary depending on the screened section and the CFU/mL values are more reliable.

![The antimicrobial activity of **F105** against biofilm-embedded MSSA **(upper)** and MRSA **(lower)** analyzed by CLSM. **F105** was added to established 24 h old biofilms with following 24 h cultivation. The scale bars indicate 10 μm.](fmicb-08-02246-g005){#F5}

![Effect of **F105** on MSSA cells viability in culture liquid (blue) and within the 24 h old biofilm layer (red) **(A)** and corresponding dose-response curves **(B)** estimated by linear regression in the logarithmic scale (full lines) with 95% confidence intervals for the regression coefficients (dashed lines) of swimming (planctonic and detached) and adherent cells. **F105** was added to 24 h old biofilms with additional 24 h cultivation. Significant differences with control could be observed at concentrations from 10 mg/L and above for swimming cells as well as from 20 mg/L and above for adherent cells by Kruskal--Wallis test at *p* \< 0.05.](fmicb-08-02246-g006){#F6}

To compare the biofilm activity of **F105** against other antimicrobials, similar experiments were performed with ampicillin, gentamicin, and benzalkonium chloride (see Supplementary Table [S2](#SM1){ref-type="supplementary-material"} for MBC values). A fourfold MBC of benzalkonium chloride was required to reduce the number of viable biofilm-embedded cells by three orders of magnitude, while even 16-fold MBC of gentamicin or ampicillin led to only 10-fold decrease of viable cells in the biofilm (**Figure [7](#F7){ref-type="fig"}**). In marked contrast, twofold MBC of **F105** reduced the viable cells of the MSSA biofilm by more than four orders of magnitude (**Figure [7](#F7){ref-type="fig"}** and Supplementary Figure [S7](#SM1){ref-type="supplementary-material"}).

![The comparison of antimicrobial activity of **F105** and various antibiotics against biofilm embedded MSSA cells. Antimicrobials were added in wells with established 24 h old biofilms and incubation was continued for 24 h at 35°C. The concentrations are given in relative units as X-fold MBC, which were as follows: 8 mg/L for ampicillin, 4 mg/L for gentamycin, 2 mg/L for benzalkonium, and 40 mg/L for **F105**.](fmicb-08-02246-g007){#F7}

Cytotoxicity and Mutagenicity
-----------------------------

No mutagenicity of **F105** was detected in the Ames test using *Salmonella typhimurium* TA98, TA100, and TA102 strains at the furanone concentrations up to 80 mg/L without (Supplementary Table [S3](#SM1){ref-type="supplementary-material"}) and with (Supplementary Table [S4](#SM1){ref-type="supplementary-material"}) metabolic activation. The cytotoxicity test provided with CC~50~ values of 40.3 mg/L for MCF-7 cells (a human breast adenocarcinoma cell line) but only 8.1 mg/L for skin fibroblast suggesting that the current structure of **F105** might be too toxic for direct use for systemic therapeutic in humans and requires further modification of the structure in order to reduce its toxicity and improve its solubility.

Discussion
==========

The biofilm formation by the methicillin-resistant *S. aureus* cells on wounds and surfaces contacting with different tissues makes bacteria inaccessible to both antimicrobials and the immune system of the host. The discovery of the natural furanones derivatives exhibiting biofilm suppression activity ([@B62], [@B61]) gave the rise to investigations of these compounds as anti-biofilm agents ([@B7]). While many 2(5*H*)-furanone derivatives interfere with AI-II quorum-sensing systems of Gram-negative bacteria blocking the biofilm formation ([@B62]; [@B28]), a number of furanones were shown to be active against gram-positive *S. epidermidis* and *B. subtilis* ([@B26]; [@B61]; [@B47]; [@B34]; [@B72]).

Here, we have shown that 3-chloro-5(*S*)-\[(1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyloxy\]-4-\[4-methylphenylsulfonyl\]-2(5*H*)-furanone (**F105**), carrying sulfonyl and *l*-menthol moieties, exhibits antibacterial activity against both planktonic and biofilm-embedded *S. aureus*. There were some reasons, why we have chosen these modifications to improve the antimicrobial activity of this furanone derivative. In particular, menthol has been shown previously to exhibit biofilm inhibiting and biofilm eliminating effects ([@B36]) and it is one of the most effective terpenes used to enhance the dermal penetration of pharmaceuticals ([@B33]). Moreover, introduction of the *l*-menthol moiety into carbamate derivatives significantly increases their anti-biofilm properties toward MRSA ([@B63]). It could be also shown that *l*-menthol increased CH~2~ stretching frequencies on either side of lipid transition and lowed the Tm by ∼2--8°C suggesting that *l*-menthol disrupts the interlamellar hydrogen-bonding network at the polar head group region and increases the hydration levels of the model lipid system, most probably by forming new aqueous channels ([@B55]). Therefore, it could be speculated that *l*-menthol moiety acts similarly in the biofilm and facilitates the diffusion of **F105** into the biofilm matrix and probably through the cell membrane. Several researchers reported that sulfonyl-containing compounds effectively repressed the growth of *Staphylococci* ([@B51]; [@B39]; [@B48]) suggesting antibacterial activity of the sulfonyl moiety ([@B53]; [@B70]). In contrast, the analogs of **F105** lacking either sulfonyl group (compound **3** on the **Figure [1](#F1){ref-type="fig"}**) or *l*-menthol moiety (3-chloro-5-hydroxy-4-\[(4-methylphenylsulfonyl)\]-2(5*H*)-furanone) exhibited no activity against *S. aureus* ([@B43]; [@B34]) suggesting the requirement of both functional groups for bactericidal activity of **F105**.

The MIC was twofold higher (20 mg/L) in the MRSA compared to the MSSA. This difference between the MSSA and MRSA laboratory strains might be attributed to the alternation of the peptidoglycan composition due to the methicillin resistance as described previously ([@B13]), which might hamper efficient cell penetration, while we did not investigate this hypothesis explicitly. The reduced susceptibility might be also related to the SCC*mec* cassette that harbor, besides the methicillin-resistance determinants (*mecA* allels), up to more than 50 open reading frames. While some of these ORFs are known to be responsible for various resistances (e.g., the *cadDX* or *arsRBC* and *arsDARBC* operons for cadmium and arsenate resistance) ([@B46]) the other are of unknown functions and might also influence the susceptibility to **F105**. However, this has not been analyzed in this work and is currently only a hypothetical assumption. The analysis of clinical MRSA isolates also indicates that there might be in general variability in the MIC between the strains, because 9/10 clinical MRSA isolates showed an MIC of **F105** of 10 mg/L. Thus we assume that 10--20 mg/L **F105** (corresponding to 25--50 μM) might be the effective MIC-range in many *staphylococci*. Comparing **F105** to other furanone derivatives, which MICs in different *S. aureus* strains were reported to range between 4.65 mg/L (15 μM) ([@B40]) and 16 mg/L (107 μM) ([@B42]), the antimicrobial activity of **F105** is moderate. However, further experiments in a broad range of clinical isolates will be needed to determine the MIC distributions of various furanones in the staphylococcal population to draw conclusion of the ecological cut-off (ECOFF), which separates the wild-type population from resistant isolate.

Comparing to other furanone derivatives and antimicrobials, the effect of **F105** in established biofilms was remarkably strong and exceeded the activity of conventional antibiotics by several orders of magnitude. This could be attributed to the assumption that, leaving the biofilm structure almost unchanged, **F105** easily penetrates the extracellular biofilm matrix and kills the matrix-embedded cells, in marked contrast to other antibiotics like gentamicin, ampicillin, chloramphenicol, or vancomycin ([@B58]; [@B68]; [@B35]; [@B71]). There are only few antibiotics with specific mechanisms of action, which show some activity in *S. aureus* biofilms, e.g., rifampin and to a lesser extent daptomycin or fluoroquinolones ([@B25]; [@B67]; [@B69]). Rifampin inhibits RNA translation, fluoroquinolones inhibit DNA transcription and amplification, while daptomycin perforates the bacterial cell membrane. The mechanism of **F105** action remains so far elusive. Our preliminary screening of the potential molecular targets of the **F105** by LC--MS mass spectrometry analysis indicated that the intracellular levels of many proteins in *S. aureus* either decreased or increased when growing at 0.5x MIC of **F105**. Most of those proteins are enzymes involved in different cellular metabolic processes (Supplementary Tables [S5](#SM1){ref-type="supplementary-material"}, [S6](#SM1){ref-type="supplementary-material"}), while it remains currently unclear, whether these processes are directly (by interaction with specific regulators) or indirectly (e.g., in course of general stress response) impacted by **F105**. These data provide no evidence that **F105** targets quorum sensing-depending processes and thus it remains rather unlikely that the observed intra-biofilm killing is conferred by quorum sensing inhibition alone. We also cannot explain the opposite biofilm-killing efficacy of **F015** on both MRSA and MSSA laboratory strains comparing to the MIC and MBC. We can only hypothesize that this effect might also originate from intra-species variability and differentially expressed **F105** targets.

No mutagenicity of **F105** was detected in the Ames test using *Salmonella typhimurium* TA98, TA100 and TA102 strains at the furanone concentrations up to 80 mg/L without (Supplementary Table [S3](#SM1){ref-type="supplementary-material"}) and with (Supplementary Table [S4](#SM1){ref-type="supplementary-material"}) metabolic activation. The cytotoxicity test provided with CC~50~ values of 40.3 mg/L for MCF-7 cells (a human breast adenocarcinoma cell line) but only 8.1 mg/L for the skin fibroblast suggesting that the current structure of **F105** might be too toxic for direct use in systemic therapeutics in humans and requires further modification of the structure in order to lower its toxicity and improve its solubility. The nearest derivative of **F105** carrying arylsulfanyl substituent instead of arylsulfonyl group (compound **3** from the scheme 1) or lacking the *l*-menthol moiety (sulfone **F70;** [@B34]) demonstrated higher CC~50~ values (32 and 45 mg/L, respectively), but exhibited no antibacterial activity even at concentrations up to 256 mg/L. These data suggest that the cytotoxicity of **F105** presumably originates from the chlorinated 2(5*H*)-furanone fragment ([@B61]; [@B37]) rather than from either sulfonyl or *l*-menthol moieties which are responsible for antibacterial effects of the studied compound.

Since the number of patients with skin wounds with MRSA infections and MRSA-related hospitalizations and deaths are continually increasing ([@B32]), the synergy of **F105** with aminoglycosides and benzalkonium chloride makes it an attractive starting point for the development of therapeutic strategies for the skin wounds treatment. Furthermore, some biocides with relatively high cytotoxicity are widely used in practice as disinfectants or local antiseptics, with miramistin or benzalkonium chloride, two biocides belonging to quaternary ammonium salts being a prominent example. Both are cytotoxic in direct contact with typical human cells, but the compounds are known as effective antiseptics for the local treatment of infected wounds with low side effects ([@B5]; [@B24]). In particular, the CC~50~ value of benzalkonium chloride for the normal human fibroblasts was reported to be 6.7 mg/L, with CC~50~/MBC ratio of 0.05 ([@B12]). For **F105** the CC~50~/MBC ratio was found to be 0.2, suggesting its higher or comparable therapeutic index in comparison with benzalkonium chloride, which is widely used as a biocide for outer treatment ([@B1]; [@B5]). Taking in account that already 0.5--0.7 mg/L of **F105** (∼15-fold less than CC~50~) decreases the MICs of aminoglycosides and benzalkonium chloride twofold, and the ability of **F105** to target the biofilm-embedded *Staphylococci*, its chemotype looks as attractive tool for combination with antimicrobials to reduce their therapeutic concentrations, as well as to decrease their side effects and to enhance the efficacy of treatment of both planktonic and biofilm-embedded bacteria.
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